Intravenous ribavirin for respiratory syncytial viral infections in pediatric hematopoietic SCT recipients

Molinos-Quintana, Águeda; Soto, César; Gómez-Rosa, M; Pérez‐Simón, J. A.; Pérez-Hurtado, José María

doi:10.1038/bmt.2012.134

Cited by 23 publications

(17 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar findings have been reported in other studies, in which a lack of aerosolized ribavirin increased the risk of mortality in HCT recipients with RSV lower respiratory tract disease [18,22] (Figure 1). A small case series described the tolerability and success of intravenous ribavirin in the treatment of 6 pediatric HCT recipients in preventing LRTI and mortality following RSV infection [24]. Similarly, intravenous and oral ribavirin were efficacious in preventing RSV LRTI in 10 adult HCT recipients with severe lymphocytopenia [25].…”

Section: Rsvmentioning

confidence: 99%

Management of Respiratory Viral Infections in Hematopoietic Cell Transplant Recipients and Patients With Hematologic Malignancies

Chemaly

Shah

Boeckh

2014

Clinical Infectious Diseases

189

185

View full text Add to dashboard Cite

Despite preventive strategies and increased awareness, a high incidence of respiratory viral infections still occur in patients with hematologic malignancies (HMs) and in recipients of hematopoietic cell transplant (HCT). Progression of these viral infections to lower respiratory tract may prove fatal, especially in HCT recipients. Increasing evidence on the successful use of ribavirin (alone or in combination with immunomodulators) for the treatment of respiratory syncytial virus infections in HM patients and HCT recipients is available from retrospective studies; however, prospective clinical trials are necessary to establish its efficacy with confidence. The impact on progression to pneumonitis and/or mortality of treating parainfluenza virus infections with available (ribavirin) or investigational (DAS181) antiviral agents still needs to be determined. Influenza infections have been successfully treated with neuraminidase inhibitors (oseltamivir or zanamivir); however, the efficacy of these agents for influenza pneumonia has not been established, and immunocompromised patients are highly susceptible to emergence of antiviral drug resistance, most probably due to prolonged viral shedding. Infection control measures and an appreciation of the complications following respiratory viral infections in immunocompromised patients remain crucial for reducing transmission. Future studies should focus on strategies to identify patients at high risk for increased morbidity and mortality from these infections and to determine the efficacy of novel or available antiviral drugs.

show abstract

Section: Rsvmentioning

confidence: 99%

Management of Respiratory Viral Infections in Hematopoietic Cell Transplant Recipients and Patients With Hematologic Malignancies

Chemaly

Shah

Boeckh

2014

Clinical Infectious Diseases

189

185

View full text Add to dashboard Cite

show abstract

“…Prolonged wheeze, fever and cough can be observed when compared to other viral factors. The progression of the disease to the lower respiratory tract in HSCT patients may result in high mortality rates (9%-29%) (2,15,25,28). The infection is generally limited to the respiratory system; however, there are cases reporting heart and liver involvement (29).…”

Section: Rsvmentioning

confidence: 99%

Viral Respiratory Tract Infections After Hematopoetic Stem Cell Transplantation in Pediatric Patients

Sağlık¹,

Çolak²

2017

J Pediatr Inf

View full text Add to dashboard Cite

Viral respiratory tract infections (VRTI) after hematopoietic stem cell/ bone marrow transplantation (HSCT) are associated with severe morbidity and mortality. Although protective measures have been increased from VRTI for HSCT patients in recent years, these infections are still a serious problem. Treatment regimens which applied for preparation of HSCT and immunosuppressive treatments, used to prevent graft versus host disease (GVHD), especially in patients who underwent allogeneic stem cell transplantation, can lead to suppression of the patients immune system and become more sensitive to the respiratory viral infectious agents. Early diagnosis and treatment are very important because they can prevent serious complications which can cause of these infections and ensure the infection control measures. Nucleic acid-based tests have begun to use widely in recent years, have provided rapid, accurate and reliable diagnosis of respiratory viral infectious agents. In particular, with the introduction of the multiplex molecular assays that able to simultaneously detect many pathogens, has facilitated the diagnosis of some pathogens which couldn't detected by conventional methods previously. In this article, VRTI, and viral respiratory infections agents encountered in HSCT performed children are presented as a literature review.

show abstract

“…Appropriate precautions should be taken to avoid environmental teratogenic exposure in pregnant healthcare workers and visitors when aerosolized ribavirin is used. A few reports have reported the use of systemic ribavirin for RSV disease: orally or intravenously as 10–30 mg/kg of body weight in three divided doses . Patients treated with systemic ribavirin should be checked for haemolysis, abnormal liver function and kidney failure.…”

Section: Treatment Of Carv Infections (Table )mentioning

confidence: 99%

Influenza and other respiratory virus infections in solid organ transplant recipients

Manuel

López‐Medrano

Kaiser

et al. 2014

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Community-acquired respiratory viruses (CARVs) are a frequent cause of disease in solid organ transplant (SOT) recipients. Lower respiratory tract infections with CARVs can be associated with significant morbidity and even mortality in this population. This article reviews the clinical manifestations of CARVs infections and summarizes the evidence-based recommendations on the preventive and therapeutic strategies to decrease the burden of these viral infections in SOT recipients.with influenza-like symptoms during the influenza season while waiting for microbiological confirmation The efficacy of ribavirin (aerosolized or oral) for the treatment of RSV infection in SOT recipients has not been determined

show abstract

Intravenous ribavirin for respiratory syncytial viral infections in pediatric hematopoietic SCT recipients

Cited by 23 publications

References 25 publications

Management of Respiratory Viral Infections in Hematopoietic Cell Transplant Recipients and Patients With Hematologic Malignancies

Management of Respiratory Viral Infections in Hematopoietic Cell Transplant Recipients and Patients With Hematologic Malignancies

Viral Respiratory Tract Infections After Hematopoetic Stem Cell Transplantation in Pediatric Patients

Influenza and other respiratory virus infections in solid organ transplant recipients

Contact Info

Product

Resources

About